PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving ¹⁷⁷ Lu-PSMA-617

Alireza Ghodsi; Lukas Owens; Ridvan Arda Demirci; Andrei Gafita; Heather H. Cheng; Jessica E. Hawley; Ruben Raychaudhuri; Hiba Khan; Rajitha Sunkara; Andrew C. Hsieh; P. Grivas; B. Montgomery; Todd Yezefski; P Nelson; Evan Y. Yu; Michael T. Schweizer; Delphine L. Chen; Roman Gulati; Amir Iravani

doi:10.1148/radiol.250649

Key Points

To evaluate the impact of PSMA PET/CT-derived total tumor volume on prediction models for survival and response in metastatic castration-resistant prostate cancer.
Utilized prostate-specific membrane antigen PET/CT imaging to derive total tumor volume.
Integrated tumor volume data with existing prediction models.
Analyzed overall survival, progression-free survival, and biochemical response to 177 Lu-PSMA-617.
Incorporating tumor volume improves the accuracy of survival prediction models.
Enhanced discriminatory ability for overall and progression-free survival outcomes.
Improved predictions for biochemical responses were observed.

Implication

Incorporating PSMA PET/CT-derived tumor volume enhances survival predictions in metastatic prostate cancer, suggesting improved assessment methods.

Abstract

Incorporating prostate-specific membrane antigen (PSMA) PET/CT–derived total tumor volume with existing prediction models for overall survival, progression-free survival, and biochemical response to 177 Lu-PSMA-617 improved their discriminatory ability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ghodsi et al. (2026) studied this question.

synapsesocial.com/papers/69cd7a6f5652765b073a7a28 https://doi.org/10.1148/radiol.250649

View at Publisher

Ask AI

Bookmark

Share

PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving ¹⁷⁷ Lu-PSMA-617

Key Points

Implication

Abstract

Discussion

Cite This Study

PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving ¹⁷⁷ Lu-PSMA-617

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading